-
Je něco špatně v tomto záznamu ?
Copolymer liquid embolization of dural arteriovenous fistulas: A 20-year single-center experience
R. Voldřich, F. Charvát, D. Netuka
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
37602898
DOI
10.1111/jon.13148
Knihovny.cz E-zdroje
- MeSH
- cévní malformace centrálního nervového systému * diagnostické zobrazování terapie MeSH
- lidé MeSH
- píštěle * farmakoterapie MeSH
- polyvinyly terapeutické užití MeSH
- retrospektivní studie MeSH
- terapeutická embolizace * metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND AND PURPOSE: Dural arteriovenous fistulas (DAVFs) with cortical venous drainage (CVD) carry significant risks of cerebral ischemia and intracranial hemorrhage. Endovascular treatment (EVT) using Onyx, a copolymer-based liquid embolic material, has become the preferred approach. However, the optimal treatment strategy for anterior cranial fossa DAVFs remains debated. METHODS: This retrospective study analyzed outcomes of EVT for DAVFs in a single center from 2002 to 2023. Patient data including demographics, clinical status, angiographic findings, embolization techniques, and outcomes were recorded. The results of the anterior fossa malformations were analyzed separately afterward. RESULTS: A total of 195 DAVFs were included in the study. The most common presenting symptom was hemorrhage (41%), most fistulas were located in the transverse and sigmoid sinus region (48%), and the majority of DAVFs had direct CVD (78%). Transarterial embolization with Onyx was the preferred treatment strategy in majority of cases (92%). Overall, 94% of patients showed improvement or stability on the modified Rankin Scale. Two patients died due to rebleeding after partial DAVF embolization. Onyx demonstrated higher immediate complete occlusion rate compared to other embolic materials (88% vs. 35%). Overall, 91% of fistulas were closed at the last follow-up. Ten anterior fossa DAVFs were treated, resulting in clinical improvement and complete occlusion in all cases. CONCLUSION: Based on the results of our study, we believe that a cure of DAVFs, including those in the anterior fossa, can be achieved in more than 90% of cases through transarterial Onyx embolization, given long-term clinical experience.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000882
- 003
- CZ-PrNML
- 005
- 20240213093435.0
- 007
- ta
- 008
- 240109s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/jon.13148 $2 doi
- 035 __
- $a (PubMed)37602898
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Voldřich, Richard $u Department of Neurosurgery and Neurooncology, Charles University in Prague, First Medical Faculty, Military University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000306427892
- 245 10
- $a Copolymer liquid embolization of dural arteriovenous fistulas: A 20-year single-center experience / $c R. Voldřich, F. Charvát, D. Netuka
- 520 9_
- $a BACKGROUND AND PURPOSE: Dural arteriovenous fistulas (DAVFs) with cortical venous drainage (CVD) carry significant risks of cerebral ischemia and intracranial hemorrhage. Endovascular treatment (EVT) using Onyx, a copolymer-based liquid embolic material, has become the preferred approach. However, the optimal treatment strategy for anterior cranial fossa DAVFs remains debated. METHODS: This retrospective study analyzed outcomes of EVT for DAVFs in a single center from 2002 to 2023. Patient data including demographics, clinical status, angiographic findings, embolization techniques, and outcomes were recorded. The results of the anterior fossa malformations were analyzed separately afterward. RESULTS: A total of 195 DAVFs were included in the study. The most common presenting symptom was hemorrhage (41%), most fistulas were located in the transverse and sigmoid sinus region (48%), and the majority of DAVFs had direct CVD (78%). Transarterial embolization with Onyx was the preferred treatment strategy in majority of cases (92%). Overall, 94% of patients showed improvement or stability on the modified Rankin Scale. Two patients died due to rebleeding after partial DAVF embolization. Onyx demonstrated higher immediate complete occlusion rate compared to other embolic materials (88% vs. 35%). Overall, 91% of fistulas were closed at the last follow-up. Ten anterior fossa DAVFs were treated, resulting in clinical improvement and complete occlusion in all cases. CONCLUSION: Based on the results of our study, we believe that a cure of DAVFs, including those in the anterior fossa, can be achieved in more than 90% of cases through transarterial Onyx embolization, given long-term clinical experience.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a polyvinyly $x terapeutické užití $7 D011145
- 650 12
- $a cévní malformace centrálního nervového systému $x diagnostické zobrazování $x terapie $7 D020785
- 650 12
- $a terapeutická embolizace $x metody $7 D004621
- 650 12
- $a píštěle $x farmakoterapie $7 D005402
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Charvát, František $u Department of Radiology, Military University Hospital, Prague, Czech Republic
- 700 1_
- $a Netuka, David $u Department of Neurosurgery and Neurooncology, Charles University in Prague, First Medical Faculty, Military University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00002833 $t Journal of neuroimaging $x 1552-6569 $g Roč. 33, č. 6 (2023), s. 926-932
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37602898 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093432 $b ABA008
- 999 __
- $a ok $b bmc $g 2049475 $s 1210576
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 33 $c 6 $d 926-932 $e 20230821 $i 1552-6569 $m Journal of neuroimaging $n J Neuroimaging $x MED00002833
- LZP __
- $a Pubmed-20240109